KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Capital Expenditures (2016 - 2025)

Teladoc Health (TDOC) has disclosed Capital Expenditures for 12 consecutive years, with $31.7 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 34.82% to $31.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.6 million through Dec 2025, up 4.68% year-over-year, with the annual reading at $118.6 million for FY2025, 4.68% up from the prior year.
  • Capital Expenditures hit $31.7 million in Q4 2025 for Teladoc Health, up from $29.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $86.7 million in Q3 2024 to a low of -$92.1 million in Q4 2022.
  • Historically, Capital Expenditures has averaged $13.4 million across 5 years, with a median of $11.2 million in 2021.
  • Biggest five-year swings in Capital Expenditures: plummeted 3251.15% in 2022 and later skyrocketed 2781.69% in 2025.
  • Year by year, Capital Expenditures stood at $2.9 million in 2021, then tumbled by 3251.15% to -$92.1 million in 2022, then surged by 101.52% to $1.4 million in 2023, then soared by 1574.64% to $23.5 million in 2024, then skyrocketed by 34.82% to $31.7 million in 2025.
  • Business Quant data shows Capital Expenditures for TDOC at $31.7 million in Q4 2025, $29.0 million in Q3 2025, and $55.1 million in Q2 2025.